Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$41.80 USD

41.80
1,914,445

-0.38 (-0.90%)

Updated Jul 15, 2024 04:00 PM ET

After-Market: $41.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Myriad Genetics' Prolaris Receives Favorable Coverage Policies

Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.

Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block

With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.

Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes

Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.

STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes

As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.

Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now

Investors continue to be optimistic about Hill-Rom (HRC) on robust domestic growth as well as solid second-quarter of fiscal 2020 results.

Abbott's (ABT) FreeStyle Libre Study Outcome Favorable

The latest study outcome aligns with the American Diabetes Association's recommended A1c level of 7% for adults with diabetes.

Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio

Investors continue to be optimistic about LabCorp (LH) on increasing demand for COVID-19 tests as well as robust first-quarter 2020 results.

Medtronic's CE Marked MiniMed 780G to Aid Diabetes Management

Medtronic's (MDT) CE Marked advanced hybrid closed loop system, MiniMed 780G, is aimed at enhancing management of type 1 diabetes.

Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS

This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.

Boston Scientific's Single-Use Duodenoscope Gets TPT Class Nod

Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.

5 Stocks Trading Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Trina Mukherjee headshot

Diagnostic Testing Remains Crucial in Combatting Coronavirus

Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.

Illumina's (ILMN) NGS Test for Detecting Coronavirus Gets EUA

Illumina's (ILMN) NGS-based test for the detection of the SARS-CoV-2 receives the FDA's EUA to enable high-volume screening.

Myriad Genetics' Test Better Predicts Drug Levels Per Study

Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.

Medtronic's StealthStation Feature Recall Classified Class I

This is not the first time, Medtronic's (MDT) StealthStation surgical navigation system is facing product recall.

Globus Medical Faces Business Loss Amid Coronavirus Crisis

Globus Medical (GMED) notes that the U.S. spine business bottomed in the first full week of April, witnessing a decline of about 70% from its pre-COVID 19 pace.

Edwards Lifesciences' SAPIEN 3 THV Cleared for Use in China

Edwards Lifesciences' (EW) SAPIEN 3 THV to be used an alternative to open-heart surgery for high and extreme-risk AS patients post approval in China.

Medtronic Resolute Onyx Gets CE Mark for 1-Month DAPT Therapy

Medtronic's (MDT) gets CE Mark recognition for a shorter DAPT indication for HBR patients with Resolute Onyx DES implantation who are at higher risk of bleeding.

IDEXX OPTI Medical Gets CE Mark for RT-PCR Coronavirus Test

This test by IDEXX (IDXX) benefits from an optimized workflow and claims to deliver greater assurance of quality and accuracy.

Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns

The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues results from robust demand for coronavirus testing and related research.

Here's Why You Should Hold on to Haemonetics Stock for Now

Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.

Qiagen (QGEN) Up 4.3% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply

Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.

Abbott Stock Down on Urgent Field Safety Notice for TactiCath

Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.

LabCorp's New Website Offers Patients Coronavirus Trial Details

LabCorp's (LH) Covance business benefits from collaborations with leading pharmaceutical and biotechnology companies.